Apoquel

RSS

oclacitinib maleate

Authorised
This medicine is authorised for use in the European Union.

Overview

Apoquel is a veterinary medicine used to treat pruritus (itching) associated with allergic dermatitis (inflammation of the skin) as well as atopic dermatitis in dogs. It contains the active substance oclacitinib.

This EPAR was last updated on 21/01/2022

Authorisation details

Product details
Name
Apoquel
Agency product number
EMEA/V/C/002688
Active substance
oclacitinib maleate
International non-proprietary name (INN) or common name
oclacitinib maleate
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QD11AH90
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
12/09/2013
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

13/12/2021 Apoquel - EMEA/V/C/002688 - X/0019

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents for dermatitis, excluding corticosteroids

Therapeutic indication

- Treatment of pruritus associated with allergic dermatitis in dogs.
- Treatment of clinical manifestations of atopic dermatitis in dogs.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
3 ratings
1 rating
1 rating